AUTHORS
Claire Harrison, DM, Lynette C.Y. Chee, PhD, MBBS, FRACP, FRCPA2, Ciro Rinaldi, MD3, Alessandra Iurlo, MD4, Chun Huat Teh, MBChB5, Francesca Palandri, MD, PhD6, Maria Laura Fox, MD7, Jennifer O'Sullivan, MB Bch BAO8, Marco Brociner, MD9, Izabela Antys, MSc10, Yury Sheykin11, Varsha Sundaresan12, Zhilin Jin, PhD13, Leopold Sellner, MD, PhD14, Florin Vranceanu15, David M. Ross, MBBS, PhD16
AFFILIATIONS
1 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
2 Department of Clinical Haematology, The Royal Melbourne Hospital and Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
3 United Lincolnshire Hospitals NHS Trust – Pilgrim Hospital, Boston, United Kingdom
4 Hematology Division, Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milano, Italy
5 St James Hospital, Leeds, United Kingdom
6 Istituto di Ematologia 'Seràgnoli', IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy
7 Vall d’Hebron University Hospital, Barcelona, Spain
8 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom
9 Azienda Socio Sanitaria Territoriale Sette Laghi, Varese, Italy
10 Phastar, London, United Kingdom
11 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
12 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
13 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
14 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
15 Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, United States
16 Department of Haematology, Flinders Medical Centre, Adelaide, South Australia, Australia, Royal Adelaide Hospital, Adelaide, South Australia, Australia
ABSTRACT
Background: Elritercept, a potent modified activin receptor type IIA ligand trap, is designed to restore effective hematopoiesis. While its effects on anemia have been demonstrated, its potential to improve additional clinically meaningful outcomes in myelofibrosis (MF) remains of considerable interest.
Methods: RESTORE (NCT05037760) is a phase 2 open-label study evaluating elritercept as monotherapy or as add-on therapy to ruxolitinib in patients (pts) with MF and anemia, including transfusion-dependent (TD; ≥3 red blood cell [RBC] units over ≥12 weeks [wks]) and non-TD pts (NTD; <3 RBC units over ≥12 wks with hemoglobin [Hb] <10g/dL). Analyses included hematological outcomes such as Hb changes and transfusion independence (TI), spleen volume reduction, symptom burden assessed by MF Symptom Assessment Form Total Symptom Score (MF-SAF TSS), fatigue assessed by Patient-Reported Outcomes Measurement Information System (PROMIS) Fatigue short form 7a, as well as, safety and changes in bone marrow fibrosis (BMF) grades and driver gene mutations.
Results: As of April 3, 2026, 102 pts with MF had received elritercept as monotherapy (n=44; previously treated with or ineligible for JAK inhibitor[s]) or added to ruxolitinib (n=58); 91 pts were evaluable for efficacy. Elritercept was associated with rapid and durable Hb improvements. Mean Hb increases were observed as early as Wk 1 (+0.79 g/dL with elritercept monotherapy; +0.90 g/dL with elritercept add-on therapy) and were maintained over time.
Among all evaluable TD pts, 28.8% (17/59) and 32.2% (19/59) achieved TI over ≥12 wks within 24 and 36 wks, respectively. With elritercept monotherapy and elritercept add-on therapy, TI rates were 20.0% (4/20) and 33.3% (13/39) within 24 wks, and 20.0% (4/20) and 38.5% (15/39) within 36 wks, respectively. Median duration of TI was not reached with elritercept monotherapy and was 57.6 wks with elritercept add-on therapy. Among all evaluable TD pts, 10.2% (6/59) and 13.6% (8/59) achieved a mean Hb increase ≥1.5 g/dL for ≥12 wks within 24 wks and 36 wks, respectively. Among all evaluable NTD pts, 31.3% (10/32) and 37.5% (12/32) achieved a sustained mean Hb increase ≥1.5 g/dL for ≥12 wks within 24 wks and 36 wks, respectively, in absence of transfusions. Furthermore, NTD response rates were 21.4% (3/14) with monotherapy and 38.9% (7/18) with add-on therapy within 24 wks, and 21.4% (3/14) and 50.0% (9/18) within 36 wks, respectively.
A ≥35% reduction in spleen volume from baseline was achieved in 5.0% (1/20) of evaluable pts with elritercept monotherapy and 17.1% (6/35) with elritercept add-on therapy; a ≥25% reduction was achieved in 5.0% (1/20) of pts receiving monotherapy and 31.4% (11/35) receiving add-on therapy. Within the first 32 wks, a ≥50% reduction in MF-SAF TSS was achieved by 2.8% (1/36) and 17.5% (7/40) of evaluable pts with monotherapy and add-on therapy, respectively. At Wk 32, the mean (standard deviation) change in MF-SAF TSS from baseline was 1.4 (11.5) with monotherapy and −2.8 (12.3) with add-on therapy. Clinically meaningful fatigue improvements were also seen in 31.8% (14/44) and 55.2% (32/58) of evaluable pts receiving monotherapy and add-on therapy, respectively, with ≥3-point reductions in PROMIS Fatigue scores at any time during treatment; ≥5-point reductions were observed in 25.0% (11/44) and 50.0% (29/58) of evaluable pts with monotherapy and add-on therapy, respectively.
Elritercept showed a favorable safety profile; 15.7% (16/102) of pts discontinued elritercept due to adverse events. Overall, 4.9% (5/102) of pts had transformation to acute myeloid leukemia. Exploratory analyses across both arms demonstrated improvement in BMF grade in 12.2% (6/49) of evaluable pts with paired biopsies. Overall, a ≥50% reduction in JAK2 V617F VAF was seen in 15.8% (6/38) of evaluable pts, 3 of whom received monotherapy.
Conclusions: Elritercept demonstrated rapid, durable Hb improvements and clinically meaningful TI in pts with MF and anemia. Beyond anemia benefit, elritercept was associated with reductions in spleen volume, overall MF-related symptom burden, pt-reported fatigue, with a favorable safety profile and modest improvements in BMF grade and JAK2 V617F VAF, supporting a broader clinical benefit and early disease-modifying activity. These data support elritercept as a differentiated therapeutic approach in MF and warrant further evaluation as an add-on therapy to ruxolitinib in the phase 3 ELRISE-MF study (NCT07623161).
DISCLOSURES
Claire Harrison, DM: Chakana Medical Limited - Current equity holder in private company; Takeda - Honoraria; Jannsen - Honoraria; AOP - Honoraria; Novartis - Honoraria; Sobi - Honoraria; Keros - Honoraria; Incyte - Honoraria; Galecto - Honoraria; Geron - Honoraria; Damora - Honoraria; Rvyu - Honoraria; BMS - Honoraria; Calitryx Bio - Honoraria; GSK - Honoraria; Novartis - Research Funding; GSK AOP - Research Funding; OPNA - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Geron - Consultancy (Includes expert testimony); Silence - Consultancy (Includes expert testimony); BMS - Consultancy (Includes expert testimony); Kartos - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); GSK AOP - Consultancy (Includes expert testimony); Syntara - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); AOP - Consultancy (Includes expert testimony); Blood Cancer UK - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Calytrix - Consultancy (Includes expert testimony); Rvyu - Consultancy (Includes expert testimony); Alethiomics. - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Mennarini Stemline - Consultancy (Includes expert testimony); Jannsen - Consultancy (Includes expert testimony); IiOMEDICO - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Galecto - Consultancy (Includes expert testimony); Incyte - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); DISC - Consultancy (Includes expert testimony); Damora - Consultancy (Includes expert testimony); Calitryx Bio - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Syntara - Consultancy (Includes expert testimony); GSK - Consultancy (Includes expert testimony); Sobi - Consultancy (Includes expert testimony); Keros - Consultancy (Includes expert testimony); Karyopharm - Consultancy (Includes expert testimony); Pharma& - Consultancy (Includes expert testimony); Keros - Consultancy (Includes expert testimony); Galecto - Consultancy (Includes expert testimony); Abbvie - Divested equity in a private or publicly-traded company in the past 24 months; Guy’s and St Thomas’ NHS Foundation Trust - Current Employment